Tendfo Medical Announces Close Of Pre-Series A and Series A Financing with Total Amount of ￥100M

(VCBeat) Aug. 2, 2021 -- Recently, Shenzhen Tendfo Medical Technology Co., Ltd. ("Tendfo Medical") has completed a Pre-Series A and Series A financing with a total amount of 100 million yuan, led by BioTrack Capital, with participation from K2VC, China Growth Capital and Cowin Capital. The successful completion of this round of financing reflects the capital market's recognition of Tendfo Medical's research and development strength in its pulmonary embolism treatment system and other products, as well as the expectation of future development. 

According to Tendfo Medical, it will focus on the further improvement of product development and the full understanding of clinical needs and strive to provide the best products, to fill the gap in the field of interventional surgical treatment of pulmonary embolism medical devices in China, and become a leader in pulmonary vascular and thrombosis treatment products and solutions.

Tendfo Medical was founded in January 2020. The company has a comprehensive product layout of pulmonary embolism and deep vein thrombosis (DVT) diseases. The thrombectomy device for pulmonary artery thrombosis independently developed by Tendfo Medical has entered the stage of clinical trial registration. In addition to the core products under clinical research, a number of other products are under testing with clinical researches being launched soon. It is believed that with the rich experience of the core team of Tendfo Medical in interventional device research and development, the company can quickly complete the development and marketing of products.

Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China. The company focuses on innovative biotech companies, innovative MedTech companies, and innovative business models in healthcare which are led by outstanding entrepreneurs.

CGC is a China-focused seed and early venture investor since 2006. We back extraordinary entrepreneurs from seed to early growth in the enterprise, frontier tech, life science, marketplace, and consumer verticals. They pioneered fintech and enterprise innovations in China since founding in 2006 with a unique portfolio of fintech, enterprise software, frontier technology, and marketplace players.